 Antidepressive Agents
"Antidepressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
| Descriptor ID |
D000928
|
| MeSH Number(s) |
D27.505.954.427.700.122
|
| Concept/Terms |
Antidepressive Agents- Antidepressive Agents
- Agents, Antidepressive
- Antidepressant Drugs
- Drugs, Antidepressant
- Antidepressants
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents".
This graph shows the total number of publications written about "Antidepressive Agents" by people in UAMS Profiles by year, and whether "Antidepressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 2 | 2 | | 2022 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2020 | 1 | 4 | 5 | | 2019 | 1 | 0 | 1 | | 2018 | 2 | 0 | 2 | | 2017 | 2 | 1 | 3 | | 2016 | 1 | 0 | 1 | | 2015 | 2 | 1 | 3 | | 2014 | 4 | 2 | 6 | | 2013 | 4 | 2 | 6 | | 2012 | 7 | 2 | 9 | | 2011 | 6 | 0 | 6 | | 2010 | 5 | 3 | 8 | | 2009 | 4 | 2 | 6 | | 2008 | 4 | 0 | 4 | | 2007 | 2 | 2 | 4 | | 2006 | 9 | 0 | 9 | | 2005 | 9 | 2 | 11 | | 2004 | 7 | 2 | 9 | | 2003 | 7 | 3 | 10 | | 2002 | 4 | 0 | 4 | | 2001 | 2 | 0 | 2 | | 2000 | 3 | 2 | 5 | | 1999 | 2 | 0 | 2 | | 1997 | 1 | 3 | 4 | | 1996 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1994 | 2 | 1 | 3 | | 1993 | 1 | 1 | 2 | | 1992 | 1 | 0 | 1 | | 1991 | 1 | 1 | 2 | | 1990 | 2 | 0 | 2 | | 1989 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antidepressive Agents" by people in Profiles over the past ten years.
-
Fortney JC, Kaysen DL, Engel CC, Cerimele JM, Nolan JP, Chase E, Blanchard BE, Hauge S, Bechtel J, Moore DL, Taylor A, Acierno R, Nagel N, Sripada RK, Painter JT, DeBeer BB, Bluett E, Teo AR, Morland LA, Heagerty PJ. Sequenced Treatment Effectiveness for Posttraumatic Stress (STEPS) Trial: A protocol for a pragmatic comparative effectiveness trial with baseline results. Contemp Clin Trials. 2024 Sep; 144:107606.
-
Baum ML, Widge AS, Carpenter LL, McDonald WM, Cohen BM, Nemeroff CB. Pharmacogenomic Clinical Support Tools for the Treatment of Depression. Am J Psychiatry. 2024 Jul 01; 181(7):591-607.
-
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022 07 12; 328(2):151-161.
-
MahmoudianDehkordi S, Ahmed AT, Bhattacharyya S, Han X, Baillie RA, Arnold M, Skime MK, John-Williams LS, Moseley MA, Thompson JW, Louie G, Riva-Posse P, Craighead WE, McDonald W, Krishnan R, Rush AJ, Frye MA, Dunlop BW, Weinshilboum RM, Kaddurah-Daouk R. Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Transl Psychiatry. 2021 03 02; 11(1):153.
-
Ramsey CM, Lynch KG, Thase ME, Gelernter J, Kranzler HR, Pyne JM, Shih MC, Stone A, Oslin DW. Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. J Affect Disord. 2021 03 01; 282:1272-1277.
-
Oslin DW, Chapman S, Duvall SL, Gelernter J, Ingram EP, Kranzler HR, Lehmann LS, Lynch JA, Lynch KG, Pyne JM, Shih MC, Stone A, Thase ME, Wray LO. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial. Contemp Clin Trials. 2021 02; 101:106247.
-
Kroska EB, Stowe ZN. Postpartum Depression: Identification and Treatment in the Clinic Setting. Obstet Gynecol Clin North Am. 2020 Sep; 47(3):409-419.
-
Gibbs HM, Price D, Delgado PL, Clothier JL, C?ceda R. Buprenorphine use for pain and suicidal ideation in severely suicidal patients. Int J Psychiatry Med. 2020 11; 55(6):387-396.
-
Alam M, Zameer S, Najmi AK, Ahmad FJ, Imam SS, Akhtar M. Thymoquinone Loaded Solid Lipid Nanoparticles Demonstrated Antidepressant-Like Activity in Rats via Indoleamine 2, 3- Dioxygenase Pathway. Drug Res (Stuttg). 2020 May; 70(5):206-213.
-
Etingen B, Grubbs KM, Harik JM. Drivers of Preference for Evidence-Based PTSD Treatment: A Qualitative Assessment. Mil Med. 2020 01 07; 185(Suppl 1):303-310.
-
Padala KP, Parkes CM, Padala PR. Neuropsychological and Functional Impact of COVID-19 on Mild Cognitive Impairment. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec; 35:1533317520960875.
-
Cohen BM. Evidence-Based Drug Treatment of Acute Depression in Bipolar Disorder. JAMA Psychiatry. 2019 12 01; 76(12):1314-1315.
-
Cohen BM, Sommer BR, Vuckovic A. Antidepressant-Resistant Depression in Patients With Comorbid Subclinical Hypothyroidism or High-Normal TSH Levels. Am J Psychiatry. 2018 07 01; 175(7):598-604.
-
Patatanian E, Claborn MK. Drug-Induced Restless Legs Syndrome. Ann Pharmacother. 2018 07; 52(7):662-672.
-
Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, Toto RD, Trivedi MH. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. JAMA. 2017 11 21; 318(19):1876-1890.
-
Suri R, Stowe ZN, Cohen LS, Newport DJ, Burt VK, Aquino-Elias AR, Knight BT, Mintz J, Altshuler LL. Prospective Longitudinal Study of Predictors of Postpartum-Onset Depression in Women With a History of Major Depressive Disorder. J Clin Psychiatry. 2017 Sep/Oct; 78(8):1110-1116.
-
Strasburger SE, Bhimani PM, Kaabe JH, Krysiak JT, Nanchanatt DL, Nguyen TN, Pough KA, Prince TA, Ramsey NS, Savsani KH, Scandlen L, Cavaretta MJ, Raffa RB. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. J Clin Pharm Ther. 2017 Apr; 42(2):147-154.
-
Newport DJ, Hostetter AL, Juul SH, Porterfield SM, Knight BT, Stowe ZN. Prenatal Psychostimulant and Antidepressant Exposure and Risk of Hypertensive Disorders of Pregnancy. J Clin Psychiatry. 2016 Nov; 77(11):1538-1545.
-
Prus AJ, Mooney-Leber SM, Berquist MD, Pehrson AL, Porter NP, Porter JH. The antidepressant drugs fluoxetine and duloxetine produce anxiolytic-like effects in a schedule-induced polydipsia paradigm in rats: enhancement of fluoxetine's effects by the a2 adrenoceptor antagonist yohimbine. Behav Pharmacol. 2015 Aug; 26(5):489-94.
-
Forester BP, Harper DG, Georgakas J, Ravichandran C, Madurai N, Cohen BM. Antidepressant effects of open label treatment with coenzyme Q10 in geriatric bipolar depression. J Clin Psychopharmacol. 2015 Jun; 35(3):338-40.
-
Emslie GJ, Wells TG, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2015 May; 25(4):293-305.
-
Helton SG, Lohoff FW. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015; 16(5):541-53.
-
Hudson TJ, Fortney JC, Pyne JM, Lu L, Mittal D. Reduction of patient-reported antidepressant side effects, by type of collaborative care. Psychiatr Serv. 2015 Mar 01; 66(3):272-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|